VEGFR-2 Protein, Mouse (HEK293, mFc)
VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (HEK293, mFc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293, with C-mFc labeled tag.
- Species: Mouse
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (HEK293, mFc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293, with C-mFc labeled tag.
Background
VEGFR-2, a tyrosine-protein kinase, serves as a crucial cell-surface receptor for VEGFA, VEGFC, and VEGFD, playing a fundamental role in angiogenesis regulation, vascular development, permeability, and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, and differentiation, as well as the reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, like isoform 2, may function as decoy receptors, particularly in negatively regulating VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the availability of free VEGFA and/or VEGFC and preventing their binding to FLT4. VEGFR-2 modulates FLT1 and FLT4 signaling through heterodimer formation. The binding of vascular growth factors to isoform 1 initiates various signaling cascades, including the activation of PLCG1, resulting in the production of diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Additionally, it mediates the activation of MAPK1/ERK2, MAPK3/ERK1, AKT1, and the phosphorylation of PIK3R1, contributing to phosphatidylinositol 3-kinase regulation and actin cytoskeleton reorganization. VEGFR-2 is indispensable for VEGFA-induced NOS2 and NOS3 expression, leading to nitric oxide production by endothelial cells, and it phosphorylates PLCG1, FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and SRC.
Technical Parameters
-
Species Mouse
-
Source HEK293
-
Tag C-mFc
-
Accession
P35918 (A20-E762)
-
Gene ID16542
-
Molecular Construction
-
N-term
-
VEGFR-2 (A20-E762)
Accession # P35918 -
mFc
-
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
KDR; Fetal Liver Kinase 1; Kinase Insert Domain Receptor; Vascular Endothelial Growth Factor Receptor 2 Variant; Vascular Endothelial Growth Factor Receptor 2; Tyrosine Kinase Growth Factor Receptor; VEGFR2; Receptor Protein-Tyrosine Kinase; FLK1; Fetal L
-
AA Sequence
ASVGLPGDFLHPPKLSTQKDILTILANTTLQITCRGQRDLDWLWPNAQRDSEERVLVTECGGGDSIFCKTLTIPRVVGNDTGAYKCSYRDVDIASTVYVYVRDYRSPFIASVSDQHGIVYITENKNKTVVIPCRGSISNLNVSLCARYPEKRFVPDGNRISWDSEIGFTLPSYMISYAGMVFCEAKINDETYQSIMYIVVVVGYRIYDVILSPPHEIELSAGEKLVLNCTARTELNVGLDFTWHSPPSKSHHKKIVNRDVKPFPGTVAKMFLSTLTIESVTKSDQGEYTCVASSGRMIKRNRTFVRVHTKPFIAFGSGMKSLVEATVGSQVRIPVKYLSYPAPDIKWYRNGRPIESNYTMIVGDELTIMEVTERDAGNYTVILTNPISMEKQSHMVSLVVNVPPQIGEKALISPMDSYQYGTMQTLTCTVYANPPLHHIQWYWQLEEACSYRPGQTSPYACKEWRHVEDFQGGNKIEVTKNQYALIEGKNKTVSTLVIQAANVSALYKCEAINKAGRGERVISFHVIRGPEITVQPAAQPTEQESVSLLCTADRNTFENLTWYKLGSQATSVHMGESLTPVCKNLDALWKLNGTMFSNSTNDILIVAFQNASLQDQGDYVCSAQDKKTKKRHCLVKQLIILERMAPMITGNLENQTTTIGETIEVTCPASGNPTPHITWFKDNETLVEDSGIVLRDGNRNLTIRRVRKEDGGLYTCQACNVLGCARAETLFIIEGAQEKTNLE
-
Predicted Molecular Mass
110.1 kDa
-
Molecular Weight
Approximately 120-135 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Glycosylation
Yes
-
Structure/Form
Monomer
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)